InvestorsHub Logo
Followers 91
Posts 7621
Boards Moderated 1
Alias Born 12/26/2009

Re: None

Thursday, 08/19/2010 11:25:32 PM

Thursday, August 19, 2010 11:25:32 PM

Post# of 890
P3 clinical trials now the leader in the race for alzimers treatment

Dr. Daniel Chain, is the inventor and patent holder for the technology platform on which most of the leading drug candidates (most visibily Bapineuzumab)
http://biomedreports.com/articles/most-popular/51039-exclusive-numerous-false-starts-by-others-dont-discourage-this-companys-search-for-alzheimers-treatment.html

Narration:

Alzheimer's affects over 30 million people worldwide.

That number is expected to double in the next 30 years.

"Early-onset" Alzheimer's can affect people as young as 40.

Dr. Chain:

We believe that the root cause for Alzheimer's disease is the accumulation of a protein known as beta-amyloid in the brain of Alzheimer's patients.


http://www.alzheimersweekly.com/Research/how-vaccines-clear-alzheimers-plaque-a800.html